We have recently found that peritumoral administration of a regulatable IL12 gene therapy in subjects with recurrent GBM showed increased inflammatory GBM infiltrates, including increased numbers of CD8 + T cells and elevated levels of tumor IFNγ [13]. The gene discussed is CD8A; the disease is neoplasm.